| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Boc-L-beta-Homoleucine
Boc-L-beta-Homoleucine (CAS#: 132549-43-0) is a protected beta-amino acid derivative used in peptide synthesis. It has a molecular formula of C12H23NO4 and a molecular weight of 245.32. It is the N-Boc protected form of L-beta-homoleucine, containing a tert-butoxycarbonyl (Boc) protecting group on the amino group and a free carboxylic acid. It is a research reagent for solid-phase and solution-phase peptide synthesis, enabling the incorporation of beta-amino acid residues into peptides. It is not a therapeutic drug.
| Targets |
Boc-L-beta-Homoleucine has no biological target. It is a synthetic building block used in organic chemistry and peptide synthesis. The Boc group protects the amino functionality during coupling reactions and is removed under acidic conditions. The beta-amino acid scaffold introduces conformational constraints into peptides, which can modulate their biological activity, stability, and receptor selectivity. It does not interact with enzymes or receptors directly.
|
|---|---|
| ln Vitro |
No biological activity data (IC50, EC50) are applicable to Boc-L-beta-Homoleucine as it is a protected amino acid building block. Its purity and enantiomeric excess are characterized by HPLC, NMR, and chiral chromatography. It is used as a reagent for incorporating beta-homoleucine into peptides. The resulting peptides may exhibit enhanced proteolytic stability and altered conformational properties.
|
| ln Vivo |
No in vivo therapeutic activity is applicable to Boc-L-beta-Homoleucine. It is not administered to animals or humans as a therapeutic. It is a reagent used in the synthesis of peptides that may be evaluated in biological studies. No pharmacokinetic, efficacy, or toxicity data are available for this building block.
|
| Enzyme Assay |
For non-cell applications, Boc-L-beta-Homoleucine is used in peptide synthesis. The carboxylic acid is activated using coupling reagents such as HATU, HBTU, or DIC/HOBt in the presence of a base. The activated species is reacted with the N-terminus of a growing peptide chain. The Boc group is removed with trifluoroacetic acid (TFA). Reaction progress is monitored by Kaiser test or HPLC.
|
| Cell Assay |
No cell-based assay is applicable to Boc-L-beta-Homoleucine as it is a synthetic reagent. It is used in the preparation of peptides that may be tested in cell assays. The resulting peptides are purified by HPLC and characterized by mass spectrometry. Their biological activity is assessed in appropriate cell-based assays depending on the peptide sequence and target.
|
| Animal Protocol |
No established in vivo animal protocol exists for Boc-L-beta-Homoleucine. It is not dosed to animals. It is a reagent used for the synthesis of peptides that may be evaluated in animal models. The resulting peptides are administered to animals, and their pharmacokinetics, efficacy, and toxicity are assessed. No independent in vivo data are available for the building block itself.
|
| Molecular Formula |
C12H23NO4
|
|---|---|
| Molecular Weight |
245.31532
|
| Exact Mass |
245.162
|
| CAS # |
132549-43-0
|
| PubChem CID |
2761526
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
374.3±25.0 °C at 760 mmHg
|
| Melting Point |
53-55℃
|
| Flash Point |
180.2±23.2 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.462
|
| LogP |
2.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
17
|
| Complexity |
268
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C[C@H](NC(OC(C)(C)C)=O)CC(O)=O)C
|
| InChi Key |
XRVAMBSTOWHUMM-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C12H23NO4/c1-8(2)6-9(7-10(14)15)13-11(16)17-12(3,4)5/h8-9H,6-7H2,1-5H3,(H,13,16)(H,14,15)/t9-/m0/s1
|
| Chemical Name |
(3S)-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0763 mL | 20.3815 mL | 40.7631 mL | |
| 5 mM | 0.8153 mL | 4.0763 mL | 8.1526 mL | |
| 10 mM | 0.4076 mL | 2.0382 mL | 4.0763 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
